PT - JOURNAL ARTICLE AU - Mauro Turrini AU - Angelo Gardellini AU - Livia Beretta AU - Lucia Buzzi AU - Stefano Ferrario AU - Sabrina Vasile AU - Raffaella Clerici AU - Andrea Colzani AU - Luigi Liparulo AU - Giovanni Scognamiglio AU - Gianni Imperiali AU - Giovanni Corrado AU - Antonello Strada AU - Marco Galletti AU - Nunzio Castiglione AU - Claudio Zanon TI - Clinical course and risk factors for in-hospital mortality of 205 patients with SARS-CoV-2 pneumonia in Como, Lombardy Region, Italy AID - 10.1101/2021.02.25.20134866 DP - 2021 Jan 01 TA - medRxiv PG - 2021.02.25.20134866 4099 - http://medrxiv.org/content/early/2021/03/05/2021.02.25.20134866.short 4100 - http://medrxiv.org/content/early/2021/03/05/2021.02.25.20134866.full AB - Importance With randomized clinical trials ongoing and vaccine still a long distance away, efforts to repurpose old medications used for other diseases provide hope for the treatment of COVID-19Objectives To examine the risk factors for in-hospital mortality and describe the effectiveness of different treatment strategies in a real-life setting of patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia.Design Real-life single-center study during the Lombardy COVID-19 outbreak.Setting Valduce Hospital in Como, Lombardy Region, Italy.Participants 205 laboratory-confirmed patients presenting with SARS-Cov-2 pneumonia requiring hospitalization.Interventions All patients received best supportive care and, based on their clinical needs and comorbidities, specific interventions that included the main drugs being tested for repurposing to treat COVID-19, such as hydroxychloroquine, anticoagulation, antiviral drugs, steroids or interleukin-6 pathway inhibitors.Main outcomes and measures Clinical, laboratory and treatment characteristics were analyzed with univariate and multivariate logistic regression methods to explore their impact on in-hospital mortality and compared with current literature data.Results Univariate analyses for clinical variables showed prognostic significance for age equal or greater than 70 years (estimated 28-days survival: 21.4 vs 67.4%; p<0.0001), presence of 2 or more relevant comorbidities (35.3 vs 61.8%; p=0.0008), ratio of arterial oxygen partial pressure to fractional inspired oxygen (P/F) less than 200 at presentation (21-days survival: 14.7 vs 52.4%;p<0.0001), high levels of lactate dehydrogenase (LDH) (26.4 vs 65.3%; p=0.0001), and elevated C-reactive protein (CRP) values (25.4 vs 74.9%; p=0.0001), while no statistical significance was found for all the other clinical variables tested. At univariate analysis for the different treatment scheduled, prognostic significance for survival was showed for intermediate or therapeutic-dose anticoagulation (estimated 28-days survival: 37.1 vs 23.4%; p=0.0001), hydroxychloroquine (35.7 vs 27.3%; p=0.0029), early antiviral therapy with lopinavir/ritonavir (60.1 vs 22.4%; p<0.0001), late short-course of steroids (47.9 vs 18.2%; p<0.0001) or tocilizumab therapy (69.4 vs 29.4%; p=0.0059). Multivariable regression confirmed increasing odds of in-hospital death associated with age older than 70 years (odds ratio 3.26, 95% CI 1.81–5.86; p<0.0001) and showed a reduction in mortality for patients treated with anticoagulant (−0.37, 0.49-0.95; p=0.0273), antiviral (−1.22, 0.16-0.54; p<0.0001), or steroids (−0.59, 0.35-0.87; p=0.0117) therapy.Conclusions and Relevance Results from this real-life single-center experience are in agreement and confirm actual literature data on SARS-CoV-2 pneumonia, both in terms of clinical risk factors for in-hospital mortality and as regards the effectiveness of the different therapies proposed for the management of COVID-19 disease. Waiting the results from randomized clinical trials, these data could help clinicians to identify patients with poor prognosis at an early stage and guide the choice between the different treatments implied in COVID-19 disease.Question Among the main drugs that have been tested for repurposing to treat COVID-19, what are the most effective medical treatments for SARS-CoV-2 pneumonia?Findings Results from these real-life cohort of 205 patients confirm at multivariate regression model an increasing odds of in-hospital death associated with age older than 70 years (OR 3.26) and a reduction in mortality for patients treated with anticoagulant (OR −0.37), antiviral lopinavir/ritonavir (OR −1.22), or steroids therapy (OR −0.59). In contrast, hydroxychloroquine and tocilizumab have not been confirmed to have a significant effect in the treatment of SARS-CoV-2 pneumonia, in accordance with the latest data from the international literature.Meaning Waiting the results from randomized clinical trials, these data could help clinicians to identify patients with poor prognosis at an early stage and guide the choice between the different treatments implied in COVID-19 disease.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors received no specific funding for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was given on 1 December 2020 by the Ethics Committee of Azienda SocioSanitaria Territoriale dei Sette Laghi - Centro Universitario (Territorial Social Health Authority of the Seven Lakes - University Center), 57 viale Borri - 21100 Varese, Italy www.asst-settelaghi.it Tel. (+39) 0332 278111All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that have been collected for this study are available from the corresponding author on reasonable request. Participant data without identifiers will be made available after approval from the corresponding author. The proposal with detailed description of study objectives and statistical analysis plan will be needed for evaluation of the reasonability to request for our data. The corresponding author will make a decision based on these materials.